GLP-1 Vision-Loss Lawsuits Pile Up Against Eli Lilly Over Zepbound and Trulicity

What Happened

Product-liability litigation against Eli Lilly over GLP-1 vision loss is expanding, according to industry reports tracking the case wave. Plaintiffs allege that tirzepatide-based medications — the injection sold as Zepbound for weight management and as Trulicity for diabetes — caused sudden, permanent eye damage consistent with NAION (non-arteritic anterior ischemic optic neuropathy), a rare condition that can blind one eye.

Law firms are actively recruiting clients, settlement estimates are circulating, and the litigation now spans multiple formulations of the same active molecule. Eli Lilly has weathered prior lawsuit waves over other products; the company maintains that no causal link has been established between its GLP-1 medications and NAION.

Who Is Affected

• Patients who developed vision loss after taking tirzepatide-based medications and are now potential claimants.
• Eli Lilly, which faces mounting legal exposure across its GLP-1 franchise while defending the safety record of its highest-revenue products.
• Prescribers, who must weigh rare-but-serious ocular risk warnings in shared decision-making.
• The wider GLP-1 category, because litigation generates safety headlines that shape patient perception of every drug in the class, regardless of manufacturer.

Timeline

• 2024-2025 — Observational studies first associate GLP-1 use with elevated NAION risk; European regulators move to list sudden vision loss as a rare side effect.
• 2025-2026 — Individual lawsuits over Zepbound- and Trulicity-linked vision loss are filed in US courts.
• September 2026 — Claim-tracking sites report growing case volumes and discuss payout ranges, while the scientific debate over causation continues.

What This Means for Researchers

The litigation wave matters scientifically even before any verdict: it forces the NAION question into formal legal discovery, where trial data, adverse-event reports, and internal communications become public record. For researchers, the key open problem remains mechanism — whether rapid metabolic changes, systemic inflammation, vascular effects, or confounding by obesity itself drives the association. Well-designed studies with verified compounds matter more than ever, because both plaintiff and defense experts will lean on the existing literature. Expect renewed attention on ocular-safety surveillance across the entire incretin class.

How to Verify Your Peptides

• Understand analytical fundamentals via how peptide testing works.
• For tirzepatide research specifically, see our tirzepatide testing guide.
• Independent batch verification is available through our third-party testing lab directory.

Safe Alternatives

• Review the full trial record in our tirzepatide and semaglutide profiles before drawing safety conclusions from litigation coverage alone.
• Consider research-stage candidates such as retatrutide only with complete analytical documentation.
• Source from suppliers in our vendor directory that publish batch-specific certificates of analysis.

Sources

• Industry reports
• Regulatory announcements